NCT06893354View on ClinicalTrials.gov

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 10, 2025

Primary Completion Date

July 20, 2027

Study Completion Date

July 20, 2027

Conditions
NSCLC
Interventions
DRUG

lorlatinib

Subjects will be registered to receive oral lorlatinib 100mg qd for 3 cycles of 4 weeks each (12 weeks total), and then underwent surgery.

DRUG

lorlatinib plus chemotherapy

Subjects will be registered to receive oral lorlatinib 100mg qd for 3 cycles of 4 weeks each (12 weeks total) plus chemotherapy, and then underwent surgery.

All Listed Sponsors
lead

The First Affiliated Hospital of Guangzhou Medical University

OTHER